PT-141 Kisspeptin Protocol Hormonal + Central Effects A 2019 clinical trial published in The Journal of Clinical Endocrinology & Metabolism found that kisspeptin-54 administration increased LH pulse frequency by 400% wi…
Read articlePT-141 Kisspeptin for Hormonal + Central Pathways A 2018 study published in the Journal of Clinical Endocrinology & Metabolism found that kisspeptin-10 administration increased LH pulse frequency by 142% within 90 minut…
Read articlePT-141 Melanotan-2 Protocol Central + Peripheral Effects Research published in the Journal of Sexual Medicine found that PT-141 (bremelanotide) increased female sexual desire scores by 37% compared to baseline through c…
Read articleStacking PT-141 + Melanotan-2 — Central vs Peripheral Most peptide stacks fail because users assume different mechanisms equal synergy. PT-141 (bremelanotide) and Melanotan-2 both activate melanocortin receptors. The sa…
Read articlePT-141 & Melanotan-2: Central vs Peripheral Effects A 2019 Phase 3 trial published in JAMA Internal Medicine found that bremelanotide (PT-141) produced statistically significant improvements in desire and arousal in pre…
Read articleLL-37 & Thymosin Alpha-1 — Antimicrobial Research Protocol LL-37 and thymosin alpha-1 represent two of the most extensively studied antimicrobial peptides in contemporary immunology research. Not because they kill bacte…
Read articleStacking LL-37 & Thymosin Alpha-1 — Antimicrobial Research Research published in the Journal of Immunology demonstrated that dual administration of cathelicidin LL-37 and thymosin alpha-1 produced bacterial clearance ra…
Read articleLL-37 BPC-157 Protocol Chronic Infection — Real Evidence Fewer than 30% of patients with treatment-resistant chronic infections achieve sustained remission with antibiotics alone. Not because the pathogen is invincible,…
Read articleStacking LL-37 + BPC-157 — Chronic Infection Protocol Chronic infections persist not because the immune system lacks antimicrobial capacity. But because tissue damage, biofilm formation, and inflammatory cascades create…
Read articleKPV BPC-157 Protocol IBD Research — Clinical Evidence A 2019 study published in the Journal of Gastroenterology found that KPV (lysine-proline-valine), a C-terminal tripeptide fragment of α-MSH, reduced colonic inflamma…
Read articleStacking KPV BPC-157 IBD Research — What Science Shows Animal models of inflammatory bowel disease treated with KPV (lysine-proline-valine) combined with BPC-157 (body protection compound-157) demonstrate faster mucosal…
Read articleLL-37 BPC-157 for Chronic Infection — Peptide Mechanisms Most chronic infections persist not because antibiotics failed to kill the pathogen. But because the damaged tissue environment allows recurrent colonisation. Res…
Read articleKPV BPC-157 for IBD Research — Peptide Mechanisms Examined Research into KPV and BPC-157 for inflammatory bowel disease (IBD) has produced some of the most compelling preclinical evidence for peptide-based mucosal repai…
Read articleVIP Thymosin Alpha-1 for CIRS Research — Real Peptides Research teams investigating Chronic Inflammatory Response Syndrome (CIRS) consistently identify two peptides as central to immune pathway correction: Vasoactive In…
Read articleVIP Thymosin Alpha-1 Protocol CIRS Research (2026) Research from the Center for Research on Biotoxin Associated Illness has identified that approximately 75% of CIRS patients show persistent immune dysregulation even af…
Read articleThymosin Alpha-1 BPC-157 for Lyme Research | Real Peptides Researchers at Stanford's Lyme Disease Research Program documented a pattern in 2024 that shifted how the field thinks about chronic Lyme treatment: patients wi…
Read articleThymosin Alpha-1 Thymalin Protocol Thymus Research Research published in the International Journal of Immunopharmacology identified thymosin alpha-1 as a toll-like receptor 9 (TLR9) modulator capable of activating dendr…
Read articleThymosin Alpha-1 BPC-157 Protocol Lyme Research A 2022 pilot study from the Johns Hopkins Center for Lyme Disease Research examined immune markers in 42 patients with post-treatment Lyme disease syndrome (PTLDS). The pa…
Read articleStacking Thymosin Alpha-1 BPC-157 Lyme Research Findings Research published in the International Journal of Antimicrobial Agents found that Borrelia burgdorferi. The spirochete responsible for Lyme disease. Persists in …
Read articleStacking Thymosin Alpha-1 VIP Long COVID Research Research from Stanford's Long COVID initiative found that up to 68% of patients with persistent symptoms six months post-infection show measurable T-cell dysfunction. No…
Read article